Aflibercept in Recurrent or Persistent CNV
Recruiting
Observational Study
Age Related Macular Degeneration
Intravitreal Injections
Diabetic Macular Edema
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 50 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 80 (estimated)
- Sponsor
- Medical University of Vienna · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Age-related macular degeneration (AMD) and diabetic retinopathy are among the most common disorders causing visual disability in elderly people. AMD leads to dysfunction and loss of photoreceptors in the central retina. Neovascular AMD (nAMD) affects visual function early in the disease process.
The purpose of the study is to evaluate the effect of switching from ranibizumab therapy to the curren…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Adults ≥ 50 years
* Patients who have been treated with ranibizumab due to wet age-related macular degeneration for up to one year
* BCVA \>= 20/400 in the study eye using ETDRS
* Willingness and ability to comply with regular visits
* Signed informed consent
Exclusion Criteri…
Contacts